This medication is commonly used to provide sustained therapeutic support for conditions related to elevated blood pressure and associated cardiovascular risk. The combination is commonly used in clinical practice when blood pressure management requires the joint action of both active ingredients.

This medication is generally used for the long-term management of essential hypertension (chronic high blood pressure), particularly in situations where symptoms related to systemic imbalance are not adequately managed by a single antihypertensive agent. The core therapeutic domains include managing chronic high pressure and addressing symptoms that create noticeable physiological strain on the cardiovascular system. It is applied to address symptoms related to heightened physiological activity, helping achieve stabilization of elevated blood pressure readings.

“This approach is considered relevant when supportive symptom management is appropriate and contributes to improved day-to-day comfort during symptomatic periods.”

This medication is often applied as a protective strategy in adult patients with hypertension who may have coexisting high-risk conditions. The use of this medication in these chronic conditions provides support that helps ease the overall symptom burden associated with vascular strain and assists with maintaining functional stability.

Quick Fact: Therapeutic Focus
Primary Use	Conditions characterized by persistent high blood pressure
Main Therapeutic Support	Supports the stabilization of blood pressure readings
Relevant Context	Symptoms related to chest discomfort (Angina)
Patient Context	Applied across clinical settings where two therapeutic agents are used

Regulatory References

1. European Commission Union Register on Lisinopril/Amlodipine

Official Eligibility Profile for Экватор

Экватор (Amlodipine and Lisinopril) is intended for use by adult patients with hypertension. Eligibility for the medicine is strictly defined by regulatory authorities based on contraindications and specific population limitations.

---

Classification	Rule Summary (Official Labeling)
Absolute Contraindications	Use is prohibited in patients with a history of angioedema (swelling) or any hypersensitivity to ACE inhibitors or Amlodipine. The drug is contraindicated during the second and third trimesters of pregnancy due to fetal toxicity risk. It must also not be used concurrently with a Neprilysin Inhibitor or with Aliskiren in patients with diabetes.
Age Limitations	Safety and effectiveness are not established for pediatric patients less than 6 years of age. A lower initial dose may be required for older adults due to potential changes in organ function.
Conditional Use	Use requires caution and close monitoring in patients with severe hepatic impairment or severe renal impairment (GFR le 30 mL/min/1.73m^2). Caution is also required in patients with conditions like severe aortic stenosis or who are volume-depleted.

The official interaction profile for Экватор (Amlodipine/Lisinopril) is structured around documented pharmacodynamic and pharmacokinetic patterns, establishing necessary co-administration constraints defined in government regulatory documents.

---

Interaction scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions:	Neprilysin Inhibitors, Potassium-Sparing Diuretics, CYP3A Inhibitors, NSAIDs, Potassium Supplements, Lithium.
Specific interacting medicines (if explicitly listed):	Simvastatin, Aliskiren, Sacubitril, Ketoconazole, Itraconazole.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic (additive hypotension, hyperkalemia); Pharmacokinetic (altered plasma concentrations via CYP3A activity, altered excretion).
Timing-based interaction rules (if applicable):	Mandatory separation: Must not be administered within 36 hours of switching to or from a Neprilysin Inhibitor.
Population-specific interaction notes (if applicable):	Renal Impairment (GFR le 30 mL/min): Decreased elimination of the Lisinopril component, increasing systemic exposure.
Interaction-related restrictions:	Simvastatin co-administration requires a maximum Simvastatin dose of 20 mg daily due to an increase in its systemic exposure.

---

Interaction classifications (high-level)

Classification	Regulatory Basis
Interaction severity classification (as defined in official documents):	Contraindicated Combinations (e.g., Neprilysin Inhibitors, Aliskiren in diabetic patients); Clinically Significant Interactions.
Regulatory basis (EMA / FDA / etc.):	Official government prescribing information.
Interaction-context constraints (as defined in official documents):	Contraindication for Aliskiren is conditional on the presence of diabetes mellitus.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with Neprilysin Inhibitors is formally contraindicated and requires a 36-hour separation period due to the risk of angioedema.
• The combination with Simvastatin requires a restriction that the Simvastatin dose must not exceed 20 mg daily because Amlodipine increases Simvastatin's systemic exposure.
• The use of Potassium-Sparing Diuretics or Potassium Supplements is associated with an additive pharmacodynamic risk of hyperkalemia.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect and increase the risk of renal impairment.
• CYP3A Inhibitors may cause a pharmacokinetic increase in Amlodipine plasma concentrations.
• Co-administration with Lithium is noted to increase serum Lithium concentrations due to altered excretion.

Connection to the overall interaction profile (2–4 sentences):

The official interaction profile documents how the two components' distinct pharmacologic classes introduce regulatory constraints. These findings establish formally contraindicated combinations, specific dose limits for interacting medicines, and mandatory time-based administration rules for certain co-administered substance classes. These constraints are described by regulatory authorities to manage altered drug exposure and additive effects.

Экватор operates via a dual mechanism of action through its components, Lisinopril and Amlodipine. Lisinopril functions as an inhibitor of the Angiotensin-Converting Enzyme (ACE) system, thereby reducing the catalytic conversion of Angiotensin I into the potent vasoconstrictor, Angiotensin II. This inhibition subsequently lowers aldosterone secretion, resulting in fluid and electrolyte changes within the renal system.

Amlodipine, a dihydropyridine calcium channel blocker, inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle cells. This inhibition causes peripheral arterial vasodilation by preventing excitation-contraction coupling in smooth muscle. The synergistic action of both components ensures a reduction in both peripheral and systemic vascular resistance. This physiological modulation leads to the lowering of systemic pressure and a reduction in cardiac afterload, decreasing the overall cardiac workload.

Official Administration Guidelines

The medicine Экватор is a fixed-dose combination (FDC) tablet of lisinopril and amlodipine, and its administration is defined to ensure appropriate use.

Entity	Instruction / Principle
Route of administration	Oral administration only. The tablet must be swallowed whole with water and should not be crushed or divided.
Dosing schedule	The recommended dose is one tablet per day. This tablet contains a fixed ratio of the two active ingredients, such as 10 mg lisinopril and 5 mg amlodipine, with the maximum dose being one tablet of the specific FDC strength.
Timing in relation to meals	The tablet may be taken regardless of food (with or without meals) and should be taken at approximately the same time each day for consistency.

---

Use Context and Patient-Specific Rules

The FDC is intended specifically for use as substitution therapy. This means it is only indicated for patients whose blood pressure is already adequately controlled when taking the equivalent doses of the individual components, lisinopril and amlodipine, concurrently as separate tablets.

Special Population Administration Rules:

• Renal Impairment: This FDC is not suitable for initial dose titration. Patients requiring dose adjustments due to renal impairment must be managed using the individual monocomponents to allow for precise dosing.
• Children and Adolescents: Use of this medicine is not recommended in patients below 18 years of age due to a lack of sufficient data on efficacy and safety.

If a dose is missed, it is recommended that it should be taken as soon as possible on the same day; however, if the time for the next scheduled dose is near, the missed dose should be skipped entirely, and the regular schedule resumed. A double dose must not be taken to compensate for the skipped dose.

Research evidence / Overview of Studies for Экватор

Evidence for use in Arterial Hypertension

The fixed-dose combination of lisinopril and amlodipine was evaluated in research involving individuals with conditions characterized by high blood pressure. Research in this area primarily involves Randomized Controlled Trials (RCTs), which are a common type of study used in research exploring how physiological measurements change over time. These trials typically examined adults conditions presenting with cycles of stability and flare-ups of elevated blood pressure.

Researchers monitored several key outcomes related to physiological strain or stress, including changes in both the upper and lower numbers of blood pressure measured in a clinic setting. Trials also examined more specific physiological markers, such as changes in the thickness of the heart muscle or the stiffness of blood vessels. Findings describe patterns observed in the studies where participants experienced changes in these measurements over defined time intervals. The research describes changes measured during the study period. Some studies included comparative monitoring against the individual components.

Long-term Studies and Follow-up

Research has also explored the patterns of blood pressure change over extended periods, with some studies following participants for one to two years. Outcomes related to systemic or functional imbalance were tracked, contributing to evidence describing how physiological measurements are recorded over sustained periods.

What is Still Uncertain About Экватор

While research has contributed to the broader evidence landscape, several areas remain unclear. Comparative evidence is lacking in some areas, particularly large head-to-head trials against all other established fixed-dose combination treatments for hypertension. Furthermore, sample sizes were modest in some of the combination trials, meaning the certainty remains low when applying findings to the entire population of people with hypertension.

The full picture of the impact on outcomes reflecting daily functioning or activity level over many years is not complete. Evidence quality varies across studies, and there is limited information for long-term outcomes regarding the specific combination's effect on major health events like heart attack or stroke. The findings describe group patterns, not personal outcomes, and highlight the ongoing need for more comprehensive research in areas where subgroup findings are uncertain.

Key Studies & References

1. Lisinopril Tablets - [Product Monograph Template - Standard] (Regulatory/Product Labeling)
2. Essential hypertension in adults - MSF Medical Guidelines

Common questions about Экватор (FAQ)

Q: What is the drug Экватор?

A: Экватор is a combination medicine that contains two active ingredients: lisinopril and amlodipine.

• Lisinopril belongs to a class of medicines called Angiotensin-Converting Enzyme (ACE) inhibitors. It works by helping to relax blood vessels, which lowers blood pressure.
• Amlodipine is a calcium channel blocker. It also helps relax blood vessels, allowing blood to flow more easily.

This combination is used to treat high blood pressure (hypertension) in adults when treatment with the individual medicines is not enough.

---

Q: How should I take Экватор?

A: You should take Экватор exactly as your doctor prescribes.

• It is usually taken once a day, with or without food.
• Swallow the tablet whole with a sufficient amount of water.
• It is best to take the medicine at the same time each day.
• If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for a missed dose.

Always follow your doctor's instructions regarding the dose and duration of treatment.

---

Q: What are the common side effects of Экватор?

A: Like all medicines, Экватор can cause side effects, although not everyone gets them. Common side effects may include:

• Dizziness, especially when standing up quickly
• Headache
• Swelling of the ankles or feet (edema)
• Fatigue or feeling weak
• Cough
• Nausea

If you experience severe swelling of the face, lips, tongue, or throat (angioedema), stop taking the medicine immediately and seek emergency medical attention, as this can be a life-threatening allergic reaction.

---

Q: Can I drink alcohol while taking Экватор?

A: It is generally recommended to limit or avoid alcohol while taking Экватор.

• Alcohol can increase the blood pressure-lowering effect of the medicine, which may cause excessive dizziness or fainting.
• Alcohol can also increase the risk of side effects like headache or dizziness.

Discuss your alcohol consumption with your doctor. They can provide advice based on your individual health condition and treatment plan.

---

Q: What foods or supplements should I avoid while taking Экватор?

A: You should take caution with certain foods and supplements while taking Экватор:

• Potassium Supplements and Potassium-Sparing Diuretics: The lisinopril component can increase potassium levels in your blood. Taking potassium supplements or using salt substitutes that contain potassium, or certain diuretics (water pills) with high potassium, can lead to dangerously high potassium levels (hyperkalemia).
• Grapefruit Juice: High consumption of grapefruit or grapefruit juice may affect the blood levels of amlodipine.

Always inform your doctor about all the supplements, herbal products, and other medicines you are taking.

How to Store and Dispose of Экватор

Экватор (Lisinopril/Amlodipine) tablets must be stored at Controlled Room Temperature, specifically between 68 F and 77 F (20 C and 25 C). The product must be kept from freezing and stored away from excess heat and moisture. To maintain stability, the medication must be stored in its original container, which should be kept tightly closed and protected from light.

Official Requirements

Storage Restriction	Requirement
Child Safety	Keep out of the sight and reach of children.
Disposal	Dispose of unused product in accordance with local regulations.

It is officially mandated that patients do not keep outdated medicine and must consult a healthcare professional regarding proper environmental disposal to avoid common household waste.